15 results
8-K
EX-10.1
GLUE
Monte Rosa Therapeutics Inc
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person
PRE 14A
GLUE
Monte Rosa Therapeutics Inc
12 Apr 23
Preliminary proxy
4:07pm
rules to be included in our annual proxy statement;
reviewing all related person transactions for potential conflict of interest situations and approving … creates any conflict of interest because Radford performs no other work for the Company besides advising the compensation, nomination and corporate
DEF 14A
o7yc pyni2
27 Apr 22
Definitive proxy
4:10pm
424B4
9kjjbn1u2ae7e
25 Jun 21
Prospectus supplement with pricing info
6:08am
S-1/A
mjo rrpjv
9 Jun 21
IPO registration (amended)
4:51pm
S-1
EX-10.6
2qdamz ydbon
4 Jun 21
IPO registration
9:07am
S-1
f5o04
4 Jun 21
IPO registration
9:07am
S-1
EX-10.5
rmpz iptz
4 Jun 21
IPO registration
9:07am
DRS/A
vxs4a2qb3yafi6nyfw6
21 May 21
Draft registration statement (amended)
12:00am
DRS
p6zt59laj
19 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next